Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

NCT07333183 is registered in ClinicalTrials.gov with Pulmovant, Inc. as lead sponsor.

NCT NCT07333183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07333183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Lead sponsor
Pulmovant, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 23, 2025
Completion date
January 31, 2028
Enrollment
20 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, fibrosis, interstitial lung disease (ild), lung diseases, pulmonary hypertension, vascular diseases